Tim Heise (Tim Heisse)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 39

Top Topics

Particulate Matter

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Journal of diabetes science and technology

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilárd Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial. British journal of clinical pharmacology (2024)
Ulrike Hoevelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes, obesity & metabolism 26 (5) (2024)
Ulrike Hoevelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2024)
Ulrike Hoevelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes, obesity & metabolism 26 (5) (2024)
Grit Andersen, Rosy Eloy, Tim Heise, Martin Gaudier, Claire Mégret, Cyril Seroussi, You-Ping Chan, Olivier Soula, Matthew C Riddle, J Hans DeVries
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes. Diabetes, obesity & metabolism (2024)
Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilárd Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial. British journal of clinical pharmacology 90 (8) (2024)
J Hans DeVries, Sascha Heckermann, Tim Heise
Absence of a glucose-lowering effect in glucose clamp procedures with a long-acting insulin analogue. Diabetes, obesity & metabolism (2024)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: A history of ambition, failure and data torturing. Diabetes, obesity & metabolism 25 (4) (2023)
Wei Chen, Jia Lu, Leona Plum-Mörschel, Grit Andersen, Eric Zijlstra, Anshun He, Tian Xie, Longling Li, Chunyue Hao, Zhongru Gan, Tim Heise
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins. Diabetes, obesity & metabolism (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Melissa K Thomas, Kieren J Mather, Chrisanthi A Karanikas, Julia P Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care (2023)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: A history of ambition, failure and data torturing. Diabetes, obesity & metabolism (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Grit Andersen, Rosy Eloy, Susanne Famulla, Tim Heise, Grégory Meiffren, Cyril Seroussi, Martin Gaudier, Claire Mégret, You-Ping Chan, Olivier Soula, Matthew C Riddle
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: A history of ambition, failure and data torturing. Diabetes, obesity & metabolism 25 (4) (2023)
Daniel Pylov, William H Polonsky, Henrik Imberg, Helen Holmer, Jarl Hellman, Magnus Wijkman, Jan Bolinder, Tim Heise, Sofia Dahlqvist, Thomas Nyström, Erik Schwarz, Irl B Hirsch, Marcus Lind
Treatment Satisfaction and Well-Being With CGM in People With T1D: An Analysis Based on the GOLD Randomized Trial. Journal of diabetes science and technology (2023)
Grit Andersen, Rosy Eloy, Susanne Famulla, Tim Heise, Grégory Meiffren, Cyril Seroussi, Martin Gaudier, Claire Mégret, You-Ping Chan, Olivier Soula, Matthew C Riddle
A co-formulation of pramlintide and insulin A21G (ADO09) improves post-prandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: A history of ambition, failure and data torturing. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: a history of ambition, failure and data torturing. Diabetes, obesity & metabolism (2023)
Tim Heise, Carolina Piras de Oliveira, Rattan Juneja, Anderson Ribeiro, Farai Chigutsa, Thomas Blevins
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro. Diabetes, obesity & metabolism 24 (9) (2022)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism (2022)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel Basal Insulin Fc (BIF, insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes mellitus. Diabetes, obesity & metabolism (2022)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism (2022)
Max L Eckstein, Felix Aberer, Florian J R Dobler, Faisal Aziz, Tim Heise, Harald Sourij, Othmar Moser
Association of HbA1c with VO 2max in Individuals with Type 1 Diabetes: A Systematic Review and Meta-Analysis. Metabolites 12 (11) (2022)
Trisha Shang, Jennifer Y Zhang, B Wayne Bequette, Jennifer K Raymond, Gerard L Coté, Jennifer L Sherr, Jessica R Castle, John C Pickup, Yarmela Pavlovic, Juan C Espinoza, Laurel H Messer, Tim Heise, Carlos E Mendez, Sarah Kim, Barry H Ginsberg, Umesh Masharani, Rodolfo J Galindo, David C Klonoff
Diabetes Technology Meeting 2020. Journal of diabetes science and technology 15 (4) (2021)
Marshall Grant, Tim Heise, Robert Baughman
Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. Clinical pharmacokinetics (2021)
Grit Andersen, Grégory Meiffren, Susanne Famulla, Tim Heise, Aymeric Ranson, Cyril Seroussi, Rosy Eloy, Martin Gaudier, Richard Charvet, You-Ping Chan, Olivier Soula, J Hans DeVries
ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes, obesity & metabolism 23 (4) (2021)
Tim Heise, Helle Linnebjerg, David Coutant, Elizabeth LaBell, Eric Zijlstra, Christoph Kapitza, Juliana M Bue-Valleskey, Qianyi Zhang, Mary Anne Dellva, Jennifer Leohr
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, obesity & metabolism 22 (10) (2020)
Arndís Finna Ólafsdóttir, Jan Bolinder, Tim Heise, William Polonsky, Magnus Ekelund, Magnus Wijkman, Aldina Pivodic, Elsa Ahlén, Erik Schwarcz, Thomas Nyström, Jarl Hellman, Irl B Hirsch, Marcus Lind
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5). Diabetes, obesity & metabolism 23 (2) (2020)
Tim Heise, Grégory Meiffren, Bertrand Alluis, Cyril Seroussi, Aymeric Ranson, Jorge Arrubla, José Correia, Martin Gaudier, Olivier Soula, Rémi Soula, J Hans DeVries, Oliver Klein, Bruce Bode
BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes, obesity & metabolism 21 (4) (2019)
Tim Heise, Charles Donnelly, Abhijit Barve, Patrick Aubonnet
Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. Diabetes, obesity & metabolism 22 (4) (2019)
Grégory Meiffren, Theresa Herbrand, Ernestos Anastassiadis, Oliver Klein, J Hans DeVries, Tim Heise, Bertrand Alluis, Claire Mégret, Martin Gaudier, Olivier Soula, Leona Plum-Mörschel
Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, obesity & metabolism 21 (7) (2019)
Grit Andersen, Grégory Meiffren, Daniela Lamers, J Hans DeVries, Aymeric Ranson, Cyril Seroussi, Bertrand Alluis, Martin Gaudier, Olivier Soula, Tim Heise
Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes, obesity & metabolism 20 (11) (2018)
Ahmed Al-Qaissi, Maria Papageorgiou, Zeeshan Javed, Tim Heise, Alan S Rigby, Andrew T Garrett, David Hepburn, Eric S Kilpatrick, Stephen L Atkin, Thozhukat Sathyapalan
Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (3) (2018)
Tim Heise, Sascha Heckermann, J Hans DeVries
Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing? Diabetes, obesity & metabolism 20 (9) (2018)
Ulrike Hoevelmann, Minna Braendholt Olsen, Ulrik Mouritzen, Daniela Lamers, Birgit Kronshage, Tim Heise
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (3) (2018)
Eric Zijlstra, Hans-Veit Coester, Tim Heise, Leona Plum-Mörschel, Ole Rasmussen, Tord Rikte, Line Kynemund Pedersen, Marianne Qvist, Thomas Sparre
Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism. Diabetes, obesity & metabolism 20 (5) (2018)
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes, obesity & metabolism 19 (7) (2017)